Literature DB >> 21430380

In vitro activities of erythromycin, tetracycline and levofloxacin alone and in dual combinations against ureaplasma spp.

Di-Qing Luo1, Jing-Ye Liu, Wei Yang, Bin Zhang, Min-Jun Yu, Yi-Mou Wu.   

Abstract

PURPOSE: It was the aim of our study to evaluate the in vitro activities of tetracycline (TET), erythromycin (ERY) and levofloxacin (LVX) alone and in dual combinations against ureaplasmas.
METHODS: The minimum inhibitory concentrations (MICs) of 51 ureaplasmal strains were determined by microdilution assay.
RESULTS: TET was the most active when the antibiotics were used alone. The combinations resulted in significantly decreased MICs for every agent compared with the use of single antibiotics (p < 0.05, respectively), except for ERY in the ERY-LVX pair (p > 0.05), and decreased the MICs more significantly in the strains with an MIC ≥4 mg/l compared with MIC <4 mg/l, except for the TET-ERY pair. The ERY-LVX pair increased ERY MICs significantly in the MIC <4 mg/l group (p < 0.05). The combinations resulted in more beneficial MICs in strains where both agents had an MIC ≥4 mg/l compared with those where either had an MIC ≥4 mg/l, as well as in strains where either agent had an MIC <4 mg/l compared with those where both had an MIC <4 mg/l.
CONCLUSIONS: Drugs in dual combinations always give more beneficial MICs against ureaplasmas than one agent alone. Combinational benefits prefer strains with a higher initial MIC.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430380     DOI: 10.1159/000323629

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

Review 1.  Rare case of Ureaplasma parvum septic arthritis in an immunocompetent patient.

Authors:  Abuzar Ali Asif; Moni Roy; Sharjeel Ahmad
Journal:  BMJ Case Rep       Date:  2020-09-08

Review 2.  Invasive Ureaplasma Infection in Patients Receiving Rituximab and Other Humoral Immunodeficiencies-A Case Report and Review of the Literature.

Authors:  Vimal V Jhaveri; Mary T Lasalvia
Journal:  Open Forum Infect Dis       Date:  2019-09-10       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.